Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Costly Drugs to Weigh on U.S. Employers’ Expenses in 2018

Divya Grover  |  September 18, 2017

(Reuters)—U.S. employers are bracing for higher health care expenses in 2018 as spending on new drugs to treat diseases, such as cancer, multiple sclerosis and hepatitis C, is expected to rise more than 7%, according to consultancy firm Mercer.1

Between 40 and 50 new specialty drugs are set to hit the market each year in the next five years, which could increase costs by $25 billion annually, Mercer said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The survey’s preliminary findings suggest that spending on specialty drugs had risen by about 15% compared with prices that were factored into 2017 health plans. These types of drugs continue to push up overall costs of prescription drugs.

“It’s not so much that the cost of any one drug is going up, but that new drugs are being introduced,” Beth Umland, Mercer’s research director for health and benefits, told Reuters.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

There are presently 2,320 drugs in active development, the consultancy said.

Last month, Novartis AG won U.S. approval for the first of a new type of potent gene-modifying immunotherapy for leukemia, a $475,000 treatment that marks the start of a potential new treatment paradigm for some cancers.

“With so many new specialty drugs in the pipeline and few well-known, brand-name drugs going off-patent in the near future, the drug cost problem will certainly get worse before it gets better,” Mercer’s U.S. health reform leader Tracy Watts said.

Companies anticipate average per-employee health costs to increase by 4.3% in 2018, the highest rate since 2011.

Early responses from the survey suggest that 46% of employers would take steps to cut costs with new strategies such as high-deductible health plan, which shift the burden of initial medical costs to patients, but have lower monthly premiums.

These plans are becoming increasingly popular among employers as they try to keep a lid on medical costs. However, this trend has contributed to higher out-of-pocket spending on healthcare for employees.

The average per-employee cost growth is estimated to rise 6%, if companies make no changes to their medical plans, according to the survey.


Reference

  1. Mercer. News release: Mercer survey shows employers face a 4.3% increase in 2018 U.S. health benefit cost, highest since 2011, but trend stable. 2017 Sep 18.

Share: 

Filed under:Drug Updates Tagged with:costsemployer-based health insuranceHealth Insurance

Related Articles

    Walmart, Home Depot Adopt Health Insurer Tactic in Drug Copay Battle

    November 14, 2018

    NEW YORK (Reuters)—Walmart and Home Depot, two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications. Large U.S. companies have started tightly managing how employees and their family members use these popular discount, or copay, cards…

    Rheumatologist Steven S. Overman Reflects on His Last Day of Practice, Future of Specialty

    November 16, 2015

    I am a few weeks post-retirement. Having written thank you notes and completed urgent home projects, I swing in a hammock at our currently fire-threatened cabin north of Winthrop, Wash., and reflect. I feel like a young boy while freely flipping pages of a hand-scribed picture book, The Principles of Uncertainty, by Maira Kalman. She…

    The RISE Registry Delivers Practice-Based Evidence to Rheumatologists

    April 15, 2019

    The advent of quality-based healthcare, such as the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), requires rheumatology professionals to demonstrate their practice is based on interventions supported by the best available evidence and that their practice, in turn, provides quality care. These requirements have increased the need for methods to measure and quantify…

    Using RISE Data in Research

    October 17, 2019

    The ACR’s RISE registry offers answers on real-world experience to researchers.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences